UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 8, 2015
OSIRIS THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Maryland |
| 001-32966 |
| 71-0881115 |
(State or other jurisdiction of |
| (Commission File Number) |
| (IRS Employer |
incorporation) |
|
|
| Identification No.) |
7015 Albert Einstein Drive, Columbia, Maryland |
| 21046 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (443) 545 - 1800
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o |
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
o |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
o |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
o |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events.
The 2015 Annual Meeting of Stockholders (the “Annual Meeting”) of Osiris Therapeutics, Inc. (the “Company”) has been scheduled for June 10, 2015. Because the Annual Meeting will be held more than 30 days from the anniversary of the Company’s 2014 Annual Meeting of Stockholders, in accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company has set a new deadline for the receipt of any stockholder proposals submitted pursuant to Rule 14a-8 under the Exchange Act for inclusion in the Company’s proxy materials for the Annual Meeting as a matter to be voted upon at the Annual Meeting. In order for any such proposal to be timely, it must be received at the offices of the Company at 7015 Albert Einstein Drive, Columbia, Maryland 21046, no later than April 22, 2015. Any such proposal shall be subject to the requirements of the proxy rules adopted under the Exchange Act. The Company currently intends to make the proxy materials for the Annual Meeting available beginning on or about May 1, 2015.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| OSIRIS THERAPEUTICS, INC. | |
|
| |
Dated: April 8, 2015 | By: | /s/ PHILIP R. JACOBY, JR. |
|
| Philip R. Jacoby, Jr. |
|
| Chief Financial Officer |